LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: Abrocitinib for atopic dermatitis.

    Uppal, Shelley K / Chat, Vipawee S / Kearns, Donovan G / Wu, Jashin J

    Lancet (London, England)

    2021  Volume 397, Issue 10270, Page(s) 195–196

    MeSH term(s) Adolescent ; Adult ; Dermatitis, Atopic/drug therapy ; Double-Blind Method ; Humans ; Pyrimidines ; Sulfonamides
    Chemical Substances Pyrimidines ; Sulfonamides ; abrocitinib (73SM5SF3OR)
    Language English
    Publishing date 2021-01-15
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(21)00036-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Dermatologists as social media contributors during the COVID-19 pandemic.

    Uppal, Shelley K / Kearns, Donovan G / Chat, Vipawee S / Wu, Jashin J

    Cutis

    2021  Volume 106, Issue 5, Page(s) 245–246

    MeSH term(s) Adolescent ; Adult ; COVID-19/complications ; COVID-19/epidemiology ; Child ; Dermatology/organization & administration ; Humans ; Skin Diseases, Viral/epidemiology ; Social Media/statistics & numerical data ; Young Adult
    Language English
    Publishing date 2021-01-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 391840-3
    ISSN 2326-6929 ; 0011-4162 ; 0151-9522
    ISSN (online) 2326-6929
    ISSN 0011-4162 ; 0151-9522
    DOI 10.12788/cutis.0112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1315: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 44: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Understanding the Potential Role of Abrocitinib in the Time of SARS-CoV-2.

    Uppal, Shelley K / Kearns, Donovan G / Chat, Vipawee S / Wu, Jashin J

    Journal of drugs in dermatology : JDD

    2021  Volume 20, Issue 7, Page(s) 806

    MeSH term(s) COVID-19/complications ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; Enzyme Inhibitors/therapeutic use ; Humans ; Janus Kinase 1/antagonists & inhibitors ; Pyrimidines/therapeutic use ; Respiratory Distress Syndrome/drug therapy ; Respiratory Distress Syndrome/etiology ; Sulfonamides/therapeutic use
    Chemical Substances Enzyme Inhibitors ; Pyrimidines ; Sulfonamides ; abrocitinib (73SM5SF3OR) ; Janus Kinase 1 (EC 2.7.10.2)
    Language English
    Publishing date 2021-07-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2145090-0
    ISSN 1545-9616
    ISSN 1545-9616
    DOI 10.36849/JDD.5544
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.

    Kearns, Donovan G / Uppal, Shelley / Chat, Vipawee S / Wu, Jashin J

    Journal of drugs in dermatology : JDD

    2021  Volume 20, Issue 5, Page(s) 582–583

    MeSH term(s) Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; COVID-19/epidemiology ; COVID-19/immunology ; Clinical Trials, Phase III as Topic/methods ; Humans ; Phosphodiesterase 4 Inhibitors/adverse effects ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Psoriasis/immunology ; Risk Factors ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Phosphodiesterase 4 Inhibitors ; Thalidomide (4Z8R6ORS6L) ; apremilast (UP7QBP99PN)
    Language English
    Publishing date 2021-05-03
    Publishing country United States
    Document type Editorial
    ZDB-ID 2145090-0
    ISSN 1545-9616
    ISSN 1545-9616
    DOI 10.36849/JDD.5730
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Ruxolitinib cream for the treatment of vitiligo.

    Uppal, Shelley K / Kearns, Donovan G / Chat, Vipawee S / Wu, Jashin J

    Lancet (London, England)

    2020  Volume 396, Issue 10264, Page(s) 1735–1736

    MeSH term(s) Humans ; Ointments ; Pyrazoles ; Vitiligo/drug therapy
    Chemical Substances Ointments ; Pyrazoles ; ruxolitinib (82S8X8XX8H)
    Language English
    Publishing date 2020-11-25
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(20)32469-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Use of systemic therapies for psoriasis in the COVID-19 era.

    Kearns, Donovan G / Uppal, Shelley / Chat, Vipawee S / Wu, Jashin J

    The Journal of dermatological treatment

    2021  Volume 33, Issue 2, Page(s) 622–625

    Abstract: Background: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.: Objective: The purpose ... ...

    Abstract Background: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.
    Objective: The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic.
    Methods: Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized.
    Results: The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy.
    Conclusion: Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis.
    MeSH term(s) COVID-19 ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology ; Psoriasis/complications ; Psoriasis/drug therapy ; Psoriasis/epidemiology
    Keywords covid19
    Language English
    Publishing date 2021-01-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.1080/09546634.2020.1775774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.

    Kearns, Donovan G / Uppal, Shelley / Chat, Vipawee S / Wu, Jashin J

    The Journal of clinical and aesthetic dermatology

    2021  Volume 14, Issue 6, Page(s) 55–59

    Abstract: Background: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.: Objective: We compared evidence-based clinical practice guidelines (CPGs) from leading ... ...

    Abstract Background: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Objective: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis.
    Methods: Guidelines from the Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NFP) Guidelines, British Association of Dermatologists guidelines (BAD), and European S3 group (ES3) were all reviewed and compared.
    Results: This analysis revealed significant overlap in the recommendations made by experts from each CPG. However, our review highlights differences in routine laboratory recommendations and the relative and absolute contraindications to use with IL-17 inhibitors.
    Conclusion: IL-17 inhibitors are an effective treatment option for psoriasis. This analysis and review of guidelines for IL-17 inhibitor use highlights the consensus in treatment protocols and areas of disagreement between CPGs.
    Language English
    Publishing date 2021-06-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2571623-2
    ISSN 1941-2789
    ISSN 1941-2789
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review.

    Chat, Vipawee S / Uppal, Shelley K / Kearns, Donovan G / Wu, Jashin J

    Dermatologic therapy

    2021  Volume 34, Issue 4, Page(s) e14974

    Abstract: The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, ... ...

    Abstract The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed and compared. Practice guidelines from the three dermatological organizations are similar with regards to treatment dosage and initiation but differ in their recommendations for baseline screening and interval laboratory monitoring, treatment in patients undergoing surgery or receiving live vaccines, and treatment contraindications. Ustekinumab is an effective and well-tolerated systemic treatment for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients. Consideration should be given to evidence-based practice guidelines of global dermatology organizations to effectively guide treatment decisions in patients with psoriasis.
    MeSH term(s) Europe ; Humans ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; United Kingdom ; United States ; Ustekinumab
    Chemical Substances Ustekinumab (FU77B4U5Z0)
    Language English
    Publishing date 2021-05-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.14974
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Management of Psoriasis With Topicals: Applying the 2020 AAD-NPF Guidelines of Care to Clinical Practice.

    Chat, Vipawee S / Kearns, Donovan G / Uppal, Shelley K / Han, George / Wu, Jashin J

    Cutis

    2022  Volume 110, Issue 2 Suppl, Page(s) 8–14

    Abstract: Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) ...

    Abstract Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published guidelines in 2020 regarding the management of psoriasis with topical therapies. These guidelines are a framework that assist clinicians treating psoriasis patients with topical agents including steroids, calcineurin inhibitors (CNIs), vitamin D analogues, retinoids (tazarotene), emollients, keratolytics (salicylic acid), anthracenes (anthralin), and keratoplastics (coal tar). This review presents these evidence-based recommendations in a form that dermatologists can readily apply to their clinical practice. The selection of an appropriate topical therapy, effective combination therapies, duration of use, and adverse events are addressed.
    MeSH term(s) Administration, Topical ; Anthralin/therapeutic use ; Calcineurin Inhibitors/therapeutic use ; Coal Tar/adverse effects ; Dermatologic Agents ; Emollients/therapeutic use ; Humans ; Psoriasis/chemically induced ; Psoriasis/drug therapy ; Retinoids/therapeutic use ; Salicylic Acid ; Steroids/therapeutic use ; Vitamin D
    Chemical Substances Calcineurin Inhibitors ; Dermatologic Agents ; Emollients ; Retinoids ; Steroids ; Vitamin D (1406-16-2) ; Coal Tar (8007-45-2) ; Salicylic Acid (O414PZ4LPZ) ; Anthralin (U8CJK0JH5M)
    Language English
    Publishing date 2022-10-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 391840-3
    ISSN 2326-6929 ; 0011-4162 ; 0151-9522
    ISSN (online) 2326-6929
    ISSN 0011-4162 ; 0151-9522
    DOI 10.12788/cutis.0573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1315: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 44: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic".

    Kearns, Donovan G / Chat, Vipawee S / Uppal, Shelley / Wu, Jashin J

    Journal of the American Academy of Dermatology

    2020  Volume 84, Issue 1, Page(s) e31–e32

    MeSH term(s) COVID-19 ; Dermatology/education ; Humans ; Internship and Residency ; Pandemics ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-09-30
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2020.09.069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top